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Pharmacological chaperone therapy for Fabry disease
By Satoshi ISHII*1,*2,†
(Communicated by Kunihiko SUZUKI, M.J.A.)
Abstract: Fabry disease is an inherited lysosomal storage disorder caused by deﬁcient ,-
galactosidase A activity. Many missense mutations in Fabry disease often cause misfolded gene
products, which leads to their retention in the endoplasmic reticulum by the quality control system;
they are then removed by endoplasmic reticulum-associated degradation. We discovered that a
potent ,-galactosidase A inhibitor, 1-deoxygalactonojirimycin, acts as a pharmacological chaperone
to facilitate the proper folding of the mutant enzyme by binding to its active site, thereby improving
its stability and traﬃcking to the lysosomes in mammalian cells. The oral administration of 1-
deoxygalactonojirimycin to transgenic mice expressing human mutant ,-galactosidase A resulted in
signiﬁcant increases in ,-galactosidase A activity in various organs, with concomitant reductions in
globotriaosylceramide, which contributes to the pathology of Fabry disease. Seventy-eight missense
mutations were found to be responsive to 1-deoxygalactonojirimycin. These data indicate that
many patients with Fabry disease could potentially beneﬁt from pharmacological chaperone
therapy.
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Introduction
Fabry disease is an X-linked lysosomal storage
disorder caused by a deﬁciency in the activity of ,-
galactosidase A (,-Gal A, EC 3.2.1.22), an enzyme
responsible for the catabolism of glycosphingolipids,
predominantly globotriaosylceramide (Gb3).1) The
progressive accumulation of Gb3 in lysosomal and
nonlysosomal compartments of cells in the skin,
heart, kidney, brain, and other tissues contributes to
the disease pathology.2),3) The major clinical mani-
festations in patients with classic Fabry disease, that
is, with no detectable ,-Gal A activity, include pain
in the distal extremities and acroparesthesia, angio-
keratoma, hypohidrosis, corneal opacity in childhood,
and progressive vasculopathy of the heart, kidney,
and central nervous system.4) In contrast, patients
with mild-form Fabry disease and residual ,-Gal A
activity are usually asymptomatic until their late
thirties. Their clinical manifestations are often
limited to the heart5),6) and kidney.7),8)
Enzyme replacement therapy for Fabry disease
has been available since 2001,9),10) and a variety of
clinical beneﬁts in patients have been reported
relating to renal function,11),12) cardiac manifesta-
tion,13),14) and pain-related quality of life.10),15) How-
ever, the treatment is expensive, with an annual cost
of approximately $200,000 per patient.16) Alternative
therapeutic strategies are needed to reduce the cost of
clinical management. In 1999, we began to develop a
new therapeutic strategy, a pharmacological chaper-
one therapy for Fabry disease, using synthesized
chemicals.17) A pharmacological chaperone is a small
molecule that can facilitate the proper folding of a
mutant protein, thereby accelerating the protein’s
mature processing and transport to its ﬁnal cellular
destination. This article focuses on the concept of this
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Characteristics of the mutant enzyme
in patients with Fabry disease
More than 500 gene mutations have been iden-
tiﬁed in patients with Fabry disease (Human Gene
Mutation Database, http://www.hgmd.cf.ac.uk) since
the ,-Gal A gene was cloned by Bishop et al.18) in
1986. Large gene rearrangements, which are easily
predicted to cause deﬁcient activity, represent less
than 10% of the mutations; instead, many of them
are single base substitutions. In our early gene
diagnosis studies,19) we identiﬁed single amino acid
substitutions in mild-form patients with Fabry
disease, who have residual activity, and we proved
that the mutant enzymes had low activity by
transiently expressing them in mammalian cells.
Although these studies conﬁrmed that the gene
mutations cause low ,-Gal A activity in mammalian
cells, we could not explain why given amino acid
substitutions resulted in low activity.
To address this question, we expressed wild-type
and Q279E mutant ,-Gal A in insect cells with
a baculovirus expression vector,20) puriﬁed the
recombinant proteins, and characterized their prop-
erties.21),22) The kinetic properties of Q279E were the
same as those of the wild-type enzyme; however, its
thermostability was low, especially at neutral pH
(Fig. 1A). We also tested the eﬀect of substrate
analogues on Q279E’s stability, because enzyme
substrates and their analogues are historically used
as enzyme stabilizers in vitro, and we discovered that
the mutant enzyme could be stabilized by adding
galactose but not glucose or mannose (Fig. 1B). The
activity of Q279E (750U/mg protein) was lower than
that of the wild-type enzyme (5050U/mg protein) in
transiently transfected COS-1 cells, and the activity
of Q279E was markedly increased by the addition
of 200mM galactose (2030U/mg protein) but not
glucose (Fig. 1C). These data indicated that the low
activity of the mutant ,-Gal A might be caused
by its low thermostability, and that the activity
could be restored by adding an active-site-binding
compound such as galactose.
Search for a potent pharmacological chaperone
Although galactose could function as a pharma-
cological chaperone, its working concentration was
too high for clinical application, because the aﬃnity
of ,-Gal A for galactose is low. Asano et al.23)–25)
reported that many glycosidases have a high aﬃnity
for iminosugars, and that iminosugars act as com-
petitive inhibitors. The inhibitors used as pharmaco-
logical chaperones must be competitive inhibitors,
because they need to dissociate from the enzyme
when it reaches its ﬁnal destination, such as the
lysosome. We therefore searched for a potent
pharmacological chaperone among iminosugars that
strongly inhibited human ,-Gal A. Twelve potent
Fig. 1. Thermostability of a mutant enzyme and eﬀect of galactose addition. In A, the thermostability of the puriﬁed wild-type and
Q279E mutant proteins (10µg/ml) was determined by incubation in 0.1M HEPES-NaOH buﬀer (pH 7.0), containing 1mg/ml bovine
serum albumin, at 37°C for the times indicated. In B, the thermostability of the mutant protein was assayed in the presence of 200mM
galactose (Gal), glucose (Glc), or mannose (Man). In C, COS-1 cells expressing wild-type or mutant ,-Gal A were cultured at 37°C in
5% CO2 in Ham’s F-10 medium supplemented with 10% FCS with or without 200mM hexose. Column 1, mock transfection;
column 2, wild-type ,-Gal A; column 3, Q279E mutant ,-Gal A; column 4, Q279E with galactose; column 5, Q279E with glucose.21)
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activity and chaperone eﬀect in patients’ cells
(Fig. 2). Of the iminosugars tested, 1-deoxygalacto-
nojirimycin (DGJ) showed the strongest eﬀect as a
pharmacological chaperone.26)
Pharmacological chaperone assists proper folding
The proper folding of newly synthesized lysoso-
mal proteins as well as membrane and secretory
proteins is prerequisite for their export from the
endoplasmic reticulum (ER). Misfolded proteins,
which are folded incorrectly, are retained in the ER
and ultimately degraded by ER-associated degrada-
tion (ERAD).27)–29) Protein misfolding has been
recognized as an important pathological cause in
many inherited diseases, including cystic ﬁbrosis, ,1-
antitrypsin deﬁciency, familial hypercholesterolemia,
and Alzheimer’s disease.30)–32) The three-dimensional
structure of human ,-Gal A is altered by single
amino acid substitutions in Fabry disease.33),34)
To distinguish properly folded from misfolded ,-
Gal A, we used trypsin treatment. The active form of
,-Gal A was resistant to trypsin treatment, while
an inactive form created by heating and denaturing
the active protein, was completely digested to short
peptides by this treatment (Fig. 3A). Cell lines
(TNK or TMK2 cells) established from transgenic
mice expressing human wild-type or R301Q mutant
,-Gal A, respectively,35) were pulse-labeled with an
[35S]Protein labeling mix for 30min. Cell lysate from
the labeled cells was treated with trypsin, and both
trypsin-treated and intact samples were immunopre-
cipitated with an anti-,-Gal A antibody. The newly
synthesized wild-type ,-Gal A was obtained as a
main 50-kD band, a large amount of which remained
after trypsin digestion (Fig. 3B). In contrast, the
newly synthesized R301Q protein appeared as a main
50-kD band with other minor bands, and only a small
amount of the 50-kD band remained after trypsin
treatment. These data indicated that the R301Q
mutation may cause a high frequency of misfolding,
resulting in the enzyme’s rapid degradation and
low residual activity in mammalian cells. We then
examined the folding of newly synthesized R301Q
mutant in the presence of DGJ. The trypsin-resistant
50-kD band of R301Q was markedly increased by
DGJ treatment, indicating that DGJ does not just
stabilize the mutant ,-Gal A, but rather facilitates
its proper folding in the ER.
Intracellular processing of mutant ,-Gal A
Wild-type ,-Gal A is synthesized as a 50-kD
precursor protein, and processed to a 46-kD mature
protein in human ﬁbroblasts.36) Similar intracellular
maturation was observed in COS-7 cells expressing
wild-type human ,-Gal A (Fig. 4A), from which the
50-kD precursor form and 46-kD mature form were
recovered in the microsomal fraction and lysosomal
fraction, respectively, after Percoll density gradient
centrifugation.37) In contrast to the wild-type en-
zyme, the R301Q mutant ,-Gal A was degraded in
these cells without undergoing maturation. Since
only properly folded proteins can be transported
out of the ER to the Golgi apparatus by the ER
quality control system,27) misfolded and incompletely
assembled proteins are retained in the ER and
eventually degraded by the ERAD. We observed
that R301Q bound to DGJ was processed from a 50-
kD band to a 46-kD band, presumably owing to the
increase in properly folded protein. Furthermore,
Fig. 2. In vitro inhibition (A) and intracellular enhancement (B)
of ,-Gal A by inhibitors. In A, the concentrations for 50%
inhibition of ,-Gal A (IC50) were determined with puriﬁed
human ,-Gal A. In B, a patient’s lymphoblasts with the R301Q
mutation were cultured in culture medium containing each
inhibitor (100µM) for 4 days. The intracellular ,-Gal A activity
was determined with 4MU-,-galactoside as a substrate. For
both A and B: 1, no addition; 2, 1-deoxynojirimycin; 3, 1-
deoxygalactonojirimycin; 4, 1,2-dideoxygalactonojirimycin; 5, ,-
homomannojirimycin; 6, ,-homoallonojirimycin; 7, ,-homoga-
lactonojirimycin; 8, N-methyl-1-deoxygalactonojirimycin; 9, N-
ethyl-1-deoxygalactonojirimycin; 10, N-propyl-1-deoxygalacto-
nojirimycin; 11, N-butyl-1-deoxygalactonojirimycin; 12, N-hy-
droxyethyl-1-deoxygalactonojirimycin; 13, O-1-C-butyl-1-deoxy-
galactonojirimycin.26)
S. ISHII [Vol. 88, 20immunoelectron microscopic examination clearly
revealed that R301Q without DGJ was retained in
the ER and was not present in lysosomes (Fig. 4B
and 4C), but in the presence of DGJ, R301Q was
transported out of the ER and reached the lysosomes
(Fig. 4D and 4E).38)
Concept of pharmacological chaperone therapy
Human ,-Gal A consists of 429 amino acids, and
after removal of the 31-residue signal sequence, its
50-kD precursor form is synthesized in the lumen of
the ER.33),39) For the wild-type enzyme, most newly
synthesized protein is properly folded and trans-
ported out of the ER. In contrast, many mutant
proteins with a single amino acid substitution, which
comprise more than half the mutations detected in
patients with Fabry disease, show misfolding char-
acterized by low thermostability at neutral pH,37) as
well as abnormal binding with BiP40) and rapid
degradation by the ERAD.37),38) The concept of
pharmacological chaperone therapy is based on the
observation that certain small molecules that bind to
the active site of ,-Gal A can facilitate the proper
folding of its mutant forms (Fig. 5).41)
Indeed, separate studies have shown that
enzyme activity in DGJ-treated, isolated lympho-
cytes from Fabry patients is markedly increased,
because of the increase in properly folded protein,17)
that the mutant enzyme in DGJ-treated cells reaches
the lysosomes,38) and that the mutant enzyme in
DGJ-treated cells degrades accumulated Gb3.42)
Although treatment with DGJ at eﬀective concen-
trations (lower than 100µM) can increase mutant ,-
Gal A activity,26) treatment with excessive concen-
trations (higher than 1mM) signiﬁcantly inhibits it,
resulting in increased Gb3 accumulation in mamma-
lian cells.43) Thus, for eﬀective and safe treatment
using this pharmacological chaperone, the appropri-
ate dose of DGJ needed to be determined in animal
models.
Mouse model for pharmacological
chaperone therapy
For the preclinical study of the eﬃcacy and
safety of DGJ, we prepared a transgenic mouse (TgM
mouse) expressing the R301Q mutant ,-Gal A.44)
Although a mouse model for Fabry disease was
previously established by disrupting the murine ,-
Gal A gene (KO mouse),45) this mouse model is not
suitable for the study of pharmacological chaperone
therapy, which requires the expression of a human
mutant enzyme. To exclude the mouse endogenous
,-Gal A activity, the TgM mouse was crossed with
the KO mouse, to generate a transgenic mouse
expressing the R301Q mutant ,-Gal A in a murine
,-Gal A knock-out background (TgM/KO mouse).35)
Fig. 3. Identiﬁcation of active and inactive forms of ,-Gal A. A
shows a schematic representation of the method for identifying
the active form of ,-Gal A by trypsin treatment. Puriﬁed ,-Gal
A( 1µ g /ml) was incubated with 100µg/ml trypsin for 10min at
37°C. Heat-inactivated ,-Gal A (95°C, for 5min) is completely
digested by this treatment, while the active form of ,-Gal A
does not change. In B, TNK or TMK2 cells established from
transgenic mice expressing human wild-type or R301Q mutant
,-Gal A, respectively, with and without DGJ treatment were
labeled with an [35S]Protein labeling mix for 30min. Cell lysates
extracted from the labeled cells were incubated with or without
100µg/ml trypsin for 10min at 37°C, and immunoprecipitated
with an anti-,-Gal A antibody. An aliquot was analyzed by
SDS-polyacrylamide gel electrophoresis and visualized by ﬂuoro-
graphy (Hamanaka, R. et al., unpublished data).
Pharmacological chaperone therapy No. 1] 21Fig. 4. Intracellular maturation and transport of R301Q mutant ,-Gal A in the presence of DGJ. In A, COS-7 cells expressing wild-type
or R301Q mutant ,-Gal A were cultured in the absence or presence of DGJ, and pulse labeled with an [35S]Protein labeling mix. After
replacing the culture medium, the labeled proteins were chased for the indicated period. Following immunoprecipitation with an anti-
,-Gal A antibody, an aliquot was analyzed by SDS-polyacrylamide gel electrophoresis and visualized by ﬂuorography.37) In B–E,
the intracellular localization of R301Q in COS-7 cells in the absence (B and C) or presence (D and E) of DGJ was analyzed
by immunoelectron microscopy. Ultrathin sections were incubated with an anti-,-Gal A antibody followed by immunogold labeling,
and examined by transmission electron microscopy. Scale bars represent 500nm, and typical gold particles are indicated by
arrowheads.38)
S. ISHII [Vol. 88, 22Fig. 5. Schematic representation of the eﬀect of DGJ on mutant ,-Gal A in the ER. After the signal peptide is clipped oﬀ during
translation, the newly synthesized protein is immediately released into the lumen of the ER. A single amino acid substitution often
causes misfolding, because the folding information of a protein chain is contained in its amino acid sequence. The misfolded mutant ,-
Gal A is retained in the ER by the quality control system, and degraded by the ERAD. In the presence of DGJ, proper folding of the
mutant enzyme is facilitated by DGJ’s binding to its active site. Appropriately folded ,-Gal A molecules are transported out of the
ER, and reach the lysosomes, their ﬁnal destination.
Fig. 6. DGJ administration increases the ,-Gal A activity in
TgM/KO mice. TgM/KO mice were given DGJ ad libitum in
the drinking water for 2 weeks at the indicated doses. The ,-Gal
A activity was then assayed in lysates from the heart, kidney,
spleen, liver, muscle, and lungs.46) The level of ,-Gal A activity
in tissues from wild-type mice was 3–50U/mg protein.
Fig. 7. Immunohistochemistry of the heart and kidney of TgM/
KO mice treated with 0.5mM DGJ for 2 weeks. Paraﬃn sections
were stained with a polyclonal anti-,-Gal A antibody and goat
anti-rabbit IgG gold (particle size, 5nm). Sections were counter-
stained with nuclear fast red.46)
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concentrations to TgM/KO mice, by adding it to
their drinking water for 2 weeks (Fig. 6), a dose-
dependent increase in ,-Gal A activity was observed
in all the major organs. At the highest DGJ dose
(0.5mM), ,-Gal A activity in the TgM/KO mice
after the 2-week treatment was increased 22.8-fold in
the heart, 4.4-fold in the kidney, 7.8-fold in the
spleen, 7.7-fold in the liver, 21.9-fold in the muscle,
and 11.3-fold in the lungs. Because the heart and
kidney are two major organs aﬀected by Fabry
disease, these organs from the DGJ-treated TgM/
KO mouse were examined immunohistochemically
(Fig. 7).46) No immunoreactive mutant ,-Gal A
could be detected in the heart of control TgM/KO
mice. However, granular immunostaining appeared
throughout the cell matrix of cardiomyocytes of
TgM/KO mice treated with DGJ. In the kidney, a
marked increase in the intensity of ,-Gal A staining
was observed in the distal convoluted tubules, and a
slight increase was seen in the proximal convoluted
tubules. These data indicated that DGJ is easily
delivered to the cardiomyocytes and distal convo-
luted tubules, where the decomposition of Gb3 is
hard to achieve by enzyme replacement therapy.47)
To elucidate how the increase in ,-Gal A
activity leads to a decrease in accumulated Gb3,
the neutral glycosphingolipids were extracted from
the kidneys of three mice treated with 0.05mM DGJ
for 4 weeks, and were subjected to TLC analysis
(Fig. 8).46) Following the DGJ treatment, a 46%
reduction in the Gb3 content of the kidney was
observed, but the amounts of GlcCer or LacCer did
not change detectably. This result clearly indicated
that the administration of DGJ at a dosage of
approximately 3mg/kg body weight/day reduces
Gb3 storage in the kidney. Treatment with DGJ at
higher concentrations may cause an inhibition of ,-
Gal A activity and an increase in the accumulation of
Gb3; however, even animals given DGJ at 300mg/kg
body weight/day did not show any increase in Gb3
content.48) Moreover, treatment with DGJ for 9
weeks at 30mg/kg body weight/day, which is 10-fold
higher than the eﬀective dose, did not cause any
abnormality in the mice, indicating that DGJ is well
tolerated by these animals.46)
Clinical application of pharmacological
chaperone therapy
The ﬁrst clinical trial of pharmacological chap-
erone therapy for Fabry disease was performed by
Frustaci et al. using galactose.49) Galactose (1g per
kg of body weight, every other day) was administered
intravenously to a patient with a cardiac variant of
Fabry disease, who had residual ,-Gal A activity as
the result of a missense mutation (G328R). He had
severe myocardial disease and was a candidate for
cardiac transplantation. After three months of treat-
ment, marked improvements in cardiac function were
observed, and the left ventricular-wall thickness was
reduced from 16mm to 14mm. The patient returned
to full-time work after 2 years of treatment.
DGJ can be given orally, because it has a
120,000-fold greater aﬃnity for human ,-Gal A
than galactose. Currently, phase 3 clinical trials for
DGJ (AmigalTM) are being conducted with male
and female Fabry disease patients (http://www.
amicustherapeutics.com). Results from the phase 2
studies indicate that Amigal is safe and well
tolerated. The treatment resulted in increased levels
of ,-Gal A in the white blood cells and kidney,
and reduced levels of Gb3 in renal interstitial
capillary cells, obtained from kidney biopsies, and
in the urine.
Pharmacological chaperone therapy is not appli-
cable to all patients with Fabry disease; it can only
be eﬀective in patients with misfolding mutations.
Table 1 summarizes the studies in which the muta-
tions responding to DGJ treatment were screened.
Seventy-eight amino acid substitutions have been
found to be responsive to DGJ treatment. These
results indicate that pharmacological chaperone
therapy could be of therapeutic beneﬁt to many
patients with Fabry disease.
Fig. 8. Eﬀect of DGJ administration on Gb3 storage in the
kidney of TgM/KO mice. Heterozygous TgM/KO mice were
treated with DGJ (0.05mM) in their drinking water for 4 weeks.
TLC analysis of the neutral glycosphingolipids extracted from
the kidney of each mouse was performed using a solvent system
of chloroform/methanol/water {60:35:8 (v/v/v)} and visualized
by spraying with orcinol/sulfuric acid reagent. GlcCer, gluco-
sylceramide; LacCer, lactosylceramide.46)
S. ISHII [Vol. 88, 24Table 1. DGJ-responsive Mutations. Summary of mutations that showed a signiﬁcant increase in ,-Gal A activity or a reduction of
lysosomal Gb3 storage upon treatment with DGJ, in the indicated reports. DGJ-responsive mutations were screened either by an
expression study or by using ﬁbroblasts or lymphoblasts established from patients with Fabry disease
Mutation Determined by expression study Assayed with patients’ cells
A20P Ishii et al.37)
N34S Benjamin et al.60)
P40S Benjamin et al.60)
T41I Wu et al.61) Shin et al.,62) Benjamin et al.60)
M42V Shimotori et al.,63) Park et al.64)
R49C Shin et al.62)
R49L Benjamin et al.60)
M51I Spada et al.,65) Ferri et al.66)
M51K Wu et al.61) Shin et al.,62) Benjamin et al.60)
E59K Ishii et al.,37) Wu et al.61) Ishii et al.37)
E66G Spada et al.65)
E66Q Ishii et al.,37) Wu et al.61) Ishii et al.,37) Benjamin et al.60)
M72V Ishii et al.37)
A73V Spada et al.65)
M76T Shimotori et al.63)
I91T Ishii et al.,37) Park et al.,64) Wu et al.61) Ishii et al.,37) Benjamin et al.60)
W95S Benjamin et al.60)
A97V Ishii et al.,37) Wu et al.61) Ishii et al.,37) Shin et al.,67) Shin et al.,62) Benjamin et al.60)
R100K Benjamin et al.60)
R112C Park et al.,64) Wu et al.61) Shin et al.,67) Shin et al.,62) Benjamin et al.60)
R112H Ishii et al.,37) Shimotori et al.,63) Wu et al.61) Ishii et al.,37) Shin et al.,67) Shin et al.,62) Benjamin et al.60)
F113I Ishii et al.,37) Spada et al.65) Ishii et al.37)
F113L Park et al.,64) Wu et al.61) Benjamin et al.60)
G128E Wu et al.61)
A143T Spada et al.,65) Wu et al.61) Shin et al.,67) Shin et al.,62) Benjamin et al.60)
G144V Wu et al.61) Benjamin et al.60)
S148N Wu et al.61) Benjamin et al.60)
A156V Ishii et al.37)
L166V Ishii et al.37)
D170V Benjamin et al.60)
C172Y Benjamin et al.60)
G183A Filoni et al.68) Filoni et al.68)
G183D Wu et al.61) Benjamin et al.60)
G183S Wu et al.61)
T194I Yam et al.42)
S201F Shin et al.62)
P205R Benjamin et al.60)
P205T Shimotori et al.,63) Wu et al.61) Shin et al.,62) Benjamin et al.60)
Y207C Benjamin et al.60)
Y207S Wu et al.61) Benjamin et al.60)
N215S Ishii et al.,37) Spada et al.,65) Wu et al.61) Ishii et al.,37) Shin et al.,62) Benjamin et al.60)
Y216C Filoni et al.68) Filoni et al.68)
H225R Wu et al.61)
S235C Benjamin et al.60)
S235F Shimotori et al.63)
D244N Wu et al.61) Benjamin et al.60)
Continued on next page:
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incorporation of recombinant ,-Gal A into ﬁbro-
blasts from a patient with Fabry disease was
markedly increased by the addition of DGJ. In the
preclinical studies by Amicus Therapeutics, they
announced that co-administration of the chaperone
with enzyme replacement therapy resulted in pro-
longed half-life of recombinant enzyme in the
circulation, increased enzyme activity in cells and
greater Gb3 reduction in tissues compared to that
seen with enzyme replacement therapy alone. Cur-
rently, phase 2 clinical trials of the combination
therapy of pharmacological chaperone and enzyme
replacement therapies are being conducted for Fabry
disease (http://www.amicustherapeutics.com).
Conclusion
Pharmacological chaperone strategy is unique,
because it involves using a competitive inhibitor
to increase the intracellular activity of a mutant
enzyme. The idea of using this technology to treat
Fabry disease was inspired by a study on the
mechanism of mutant enzyme loss.17),21) The inhib-
itor facilitates the proper folding of mutant enzymes
in the ER, resulting in maturation of the protein and
its transport to lysosomes. Evidence suggests that
this therapeutic strategy will be applicable to other
lysosomal storage disorders51)–55) and other confor-
mational diseases.56)–59)
Continued:
Mutation Determined by expression study Assayed with patients’ cells
G258V Shimotori et al.63)
P259R Wu et al.61) Shin et al.62)
G260A Shimotori et al.63)
N263S Wu et al.61) Benjamin et al.60)
S276G Wu et al.61) Shin et al.,62) Benjamin et al.60)
Q279E Ishii et al.,37) Wu et al.61) Fan et al.,17) Ishii et al.,37) Benjamin et al.60)
T282A Shimotori et al.63)
W287C Wu et al.61) Benjamin et al.60)
A288P Wu et al.61) Benjamin et al.60)
I289F Wu et al.61) Benjamin et al.60)
M290L Ferri et al.66)
F295C Wu et al.61) Shin et al.62)
M296I Ishii et al.,37) Wu et al.61) Ishii et al.,37) Benjamin et al.60)
M296V Ishii et al.,37) Wu et al.61) Ishii et al.,37) Benjamin et al.60)
L300P Wu et al.61) Shin et al.,67) Shin et al.,62) Benjamin et al.60)
R301Q Ishii et al.,37) Wu et al.61) Fan et al.,17) Ishii et al.,37) Shin et al.,67) Shin et al.,62)
Benjamin et al.60)
K308N Shimotori et al.63)
Q312R Shimotori et al.63)
N320Y Wu et al.61) Benjamin et al.60)
G325D Wu et al.61) Benjamin et al.60)
G328A Wu et al.61) Shin et al.,62) Benjamin et al.60)
R342Q Benjamin et al.60)
R356W Wu et al.61) Benjamin et al.60)
E358A Wu et al.61) Benjamin et al.60)
E358K Benjamin et al.60)
R363C Wu et al.61) Benjamin et al.60)
R363H Wu et al.61) Benjamin et al.60)
G373D Ishii et al.37)
G373S Ishii et al.37)
V390fsX8 Yam et al.42)
L403S Shimotori et al.63)
P409A Wu et al.61) Benjamin et al.60)
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